[Phase II study with etoposide/vincristine in small cell bronchial cancer (extensive disease)].
von Pawel J, H. Wilke, Dominic Vallée, H Dimbeck, Hans‐Joachim Schmoll
Abstract
von Pawel J, H. Wilke, Dominic Vallée, H Dimbeck, Hans‐Joachim Schmoll
Abstract
The remission rates achieved with the combination of vincristine and etoposide are comparable with other frequently employed therapeutic regimens (ACO/EPICO, cisplatin/etoposide). The combination of etoposide with vincristine represents an alternative, in particular with respect to a merely palliative approach to treatment.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The remission rates achieved with the combination of vincristine and etoposide are comparable with other frequently employed therapeutic regimens (ACO/EPICO, cisplatin/etoposide). The combination of etoposide with vincristine represents an alternative, in particular with respect to a merely palliative approach to treatment.
Key concepts: Etoposide, Vincristine, Medicine, Oncology, Cisplatin, Internal medicine, Chemotherapy, Cyclophosphamide